• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类物质使用障碍渴求评估:阿片类物质渴求 VAS 的心理测量学评估和预测效度。

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.

机构信息

Bradford Health Services, Birmingham, AL, United States.

Boulder Care, Portland, OR, United States.

出版信息

Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109057. doi: 10.1016/j.drugalcdep.2021.109057. Epub 2021 Sep 24.

DOI:10.1016/j.drugalcdep.2021.109057
PMID:34794061
Abstract

BACKGROUND

This work evaluated the psychometric properties of the single-item Opioid Craving Visual Analog Scale (OC-VAS) for opioid use disorder (OUD).

METHODS

Psychometric evaluation of the OC-VAS (range: 0-100 mm) was supported by Subjective Opiate Withdrawal Scale (SOWS) item 16 and total score, Clinical Opiate Withdrawal Scale (COWS) scores, and the 36-Item Short-Form Health Survey, using data from phase 3 study (NCT02357901; N = 487) participants who received randomized treatment and completed the OC-VAS at screening. Descriptive properties, test-retest reliability, construct validity, known-groups validity, and responsiveness were assessed. Interpretation of meaningful change and predictive validity were also explored.

RESULTS

Descriptive properties for the OC-VAS at screening did not provide evidence of problematic floor/ceiling effects or missingness. The test-retest reliability was established by weekly intraclass correlations >0.70. At the screening and end of the study, the strong positive correlations between OC-VAS and SOWS Total/Item 16 score and the significant OC-VAS differences among COWS severity groups supported construct validity and known-groups (discriminating ability) validity, respectively. The associations between the changes in OC-VAS and in supporting measures/opioid use from screening to the end of the study demonstrated responsiveness and the ability to detect change in clinical status. During the induction and randomization treatment periods, significant relationships were identified between OC-VAS score and subsequent opioid use.

CONCLUSIONS

This psychometric evaluation of the OC-VAS performed on a large OUD patient population provides evidence to support its use to measure the severity of opioid craving and its ability to predict opioid use.

摘要

背景

本研究评估了用于阿片类药物使用障碍(OUD)的单项目阿片类药物渴求视觉模拟量表(OC-VAS)的心理测量特性。

方法

使用第 3 阶段研究(NCT02357901;N=487)参与者的数据,通过主观阿片戒断量表(SOWS)第 16 项和总分、临床阿片戒断量表(COWS)评分和 36 项简短健康调查问卷,对 OC-VAS(范围:0-100mm)进行心理测量评估。评估了描述性特征、重测信度、结构有效性、已知组有效性和反应性。还探讨了有意义变化的解释和预测有效性。

结果

筛选时 OC-VAS 的描述性特征没有提供存在问题的地板/天花板效应或缺失值的证据。每周的组内相关系数>0.70 确定了重测信度。在筛选和研究结束时,OC-VAS 与 SOWS 总分/第 16 项评分之间的强烈正相关,以及 COWS 严重程度组之间的 OC-VAS 差异具有统计学意义,这分别支持了结构有效性和已知组(区分能力)有效性。OC-VAS 和从筛选到研究结束时支持措施/阿片类药物使用变化之间的关联表明了反应性和检测临床状态变化的能力。在诱导和随机治疗期间,OC-VAS 评分与随后的阿片类药物使用之间存在显著关系。

结论

对大量 OUD 患者群体进行的 OC-VAS 心理测量评估提供了证据,支持其用于测量阿片类药物渴求的严重程度及其预测阿片类药物使用的能力。

相似文献

1
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.阿片类物质使用障碍渴求评估:阿片类物质渴求 VAS 的心理测量学评估和预测效度。
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109057. doi: 10.1016/j.drugalcdep.2021.109057. Epub 2021 Sep 24.
2
Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification.对接受阿片类药物脱毒治疗的患者进行10项简短阿片类药物戒断量表-戈索普(SOWS-Gossop)的心理测量评估。
Addict Behav. 2016 Sep;60:109-16. doi: 10.1016/j.addbeh.2016.03.028. Epub 2016 Apr 1.
3
Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment.衡量阿片类物质使用障碍的康复情况:治疗效果评估的临床效用和心理测量特性
Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361. eCollection 2019.
4
Craving and opioid use disorder: A scoping review.渴求与阿片类物质使用障碍:范围综述。
Drug Alcohol Depend. 2019 Dec 1;205:107639. doi: 10.1016/j.drugalcdep.2019.107639. Epub 2019 Oct 17.
5
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.临床阿片戒断量表(COWS)及单项指标与临床麻醉品评估(CINA)阿片戒断工具的同步效度验证。
Drug Alcohol Depend. 2009 Nov 1;105(1-2):154-9. doi: 10.1016/j.drugalcdep.2009.07.001. Epub 2009 Aug 3.
6
Craniofacial pain and disability inventory (CF-PDI): development and psychometric validation of a new questionnaire.颅面疼痛与功能障碍量表(CF-PDI):一种新问卷的编制及心理测量学验证
Pain Physician. 2014 Jan-Feb;17(1):95-108.
7
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.接受伊博加因进行阿片类药物脱毒治疗的参与者在戒断和渴求评分上的变化。
J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.
8
Reliability, validity and sensitivity of a computerized visual analog scale measuring state anxiety.一种测量状态焦虑的计算机化视觉模拟量表的信度、效度和敏感性。
J Behav Ther Exp Psychiatry. 2014 Dec;45(4):447-53. doi: 10.1016/j.jbtep.2014.06.004. Epub 2014 Jun 18.
9
Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS).荷兰语版主观阿片类药物戒断量表(SOWS)的心理测量学评估。
Eur Addict Res. 2007;13(2):81-8. doi: 10.1159/000097937.
10
Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.验证瘙痒数字评定量表在结节性痒疹相关瘙痒中的心理测量特性:一项随机临床试验的二次分析。
JAMA Dermatol. 2020 Dec 1;156(12):1354-1358. doi: 10.1001/jamadermatol.2020.3071.

引用本文的文献

1
Pilot testing a novel remotely delivered intensive outpatient program for hospitalized patients with opioid use disorder.对一种新型的远程提供给患有阿片类药物使用障碍的住院患者的强化门诊项目进行试点测试。
Addict Sci Clin Pract. 2025 Aug 1;20(1):61. doi: 10.1186/s13722-025-00589-4.
2
Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial.快速静脉注射症状抑制性芬太尼诱导法(SIFI),以优化使用非正规芬太尼者向口服阿片类激动剂疗法的转换:一项开放标签、单臂临床试验方案
Addict Sci Clin Pract. 2025 Jul 29;20(1):58. doi: 10.1186/s13722-025-00586-7.
3
Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder: A Double-Blind, Placebo-Controlled Randomized Trial.
阿片类物质使用障碍患者的深部经颅磁刺激:一项双盲、安慰剂对照随机试验
Addict Biol. 2025 Jun;30(6):e70057. doi: 10.1111/adb.70057.
4
Effectiveness of Attentional Bias Modification Combined With Cognitive Behavioral Therapy in Reducing Relapse Risk and Cravings in Male Patients With Alcohol Use Disorder: A Quasi-Randomized Controlled Trial.注意力偏差修正联合认知行为疗法对降低酒精使用障碍男性患者复发风险及渴望程度的有效性:一项半随机对照试验
Neuropsychopharmacol Rep. 2025 Mar;45(1):e70002. doi: 10.1002/npr2.70002.
5
Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.仅通过远程医疗治疗阿片类药物使用障碍时的丁丙诺啡停药:一项纵向队列分析。
J Subst Use Addict Treat. 2024 Dec;167:209511. doi: 10.1016/j.josat.2024.209511. Epub 2024 Sep 5.
6
Pain medication tapering for patients with Persistent Spinal Pain Syndrome Type II, treated with Spinal Cord Stimulation: A RCT-study protocol of the PIANISSIMO study.脊髓刺激治疗慢性脊柱疼痛综合征 II 型患者的疼痛药物逐渐减量:PIANISSIMO 研究的 RCT 研究方案。
PLoS One. 2024 Aug 12;19(8):e0302842. doi: 10.1371/journal.pone.0302842. eCollection 2024.
7
Patients' perspectives on buprenorphine subcutaneous implant: a case series.患者对丁丙诺啡皮下植入物的看法:病例系列。
J Med Case Rep. 2024 Apr 6;18(1):202. doi: 10.1186/s13256-024-04483-6.
8
The relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder.疼痛强度和阿片类药物渴求与延迟美沙酮剂量的关系:阿片类药物使用障碍个体的初步研究。
Br J Clin Pharmacol. 2024 Dec;90(12):2977-2984. doi: 10.1111/bcp.16027. Epub 2024 Mar 4.
9
Beyond mediators: A critical review and methodological path forward for studying mechanisms in alcohol use treatment research.超越中介因素:酒精使用治疗研究中机制研究的批判性综述与方法学前进路径
Alcohol Clin Exp Res (Hoboken). 2024 Feb;48(2):215-229. doi: 10.1111/acer.15242. Epub 2023 Dec 27.
10
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.考察对接受阿片类物质使用障碍治疗的注射阿片类药物参与者给予更高维持剂量的丁丙诺啡缓释制剂的益处。
Harm Reduct J. 2023 Dec 2;20(1):173. doi: 10.1186/s12954-023-00906-7.